Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immucell (ICCC) Equity Ratio (2016 - 2025)

Immucell (ICCC) has disclosed Equity Ratio for 16 consecutive years, with 0.65 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Equity Ratio rose 9.67% year-over-year to 0.65, compared with a TTM value of 0.65 through Sep 2025, up 9.67%, and an annual FY2024 reading of 0.61, up 6.95% over the prior year.
  • Equity Ratio was 0.65 for Q3 2025 at Immucell, up from 0.64 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.74 in Q2 2021 and bottomed at 0.56 in Q2 2024.
  • Average Equity Ratio over 5 years is 0.65, with a median of 0.65 recorded in 2025.
  • The sharpest move saw Equity Ratio dropped 15.76% in 2023, then grew 14.08% in 2025.
  • Year by year, Equity Ratio stood at 0.73 in 2021, then decreased by 7.56% to 0.68 in 2022, then decreased by 15.76% to 0.57 in 2023, then rose by 6.95% to 0.61 in 2024, then rose by 6.8% to 0.65 in 2025.
  • Business Quant data shows Equity Ratio for ICCC at 0.65 in Q3 2025, 0.64 in Q2 2025, and 0.64 in Q1 2025.